Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | CAR-T for myeloma: the show must go on

Mohamad Mohty • 31 Mar 2020
Multiple Myeloma
CARTITUDE-1

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the use of CAR T-cell therapy in R/R multiple myeloma. Specifically, Prof. Mohty touches on advances in cellular therapies, the very encouraging results being seen from current research and the movement of CAR-T into the frontline. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Mohamad Mohty

Advances in GvHD management presented at ASH 2025 5:07
Advances in GvHD management presented at ASH 2025
Mohamad Mohty • 5 Dec 2025
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Mohamad Mohty et al. • 15 Jul 2022
Optimizing conditioning regimens for SCT in AML and MDS 3:38
Optimizing conditioning regimens for SCT in AML and MDS
Mohamad Mohty • 31 Mar 2025
Optimizing anti-CD38 monoclonal antibody-based quadruplet therapies in newly diagnosed myeloma 4:28
Optimizing anti-CD38 monoclonal antibody-based quadruplet therapies in newly diagnosed myeloma
Mohamad Mohty • 31 Mar 2025

Related Videos

A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals